Atlas Trials

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Clinical trial NCT03518086 · COMPLETED

Trial details

NCT number
NCT03518086
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Ulcerative Colitis
Start date
2018-06-18
Primary completion
2021-01-21
Enrollment
1281

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.